Exploring Outcome Measures for Mitochondrial Myopathies; Insights From a Longitudinal Study on TK2 Deficiency
Journal of Inherited Metabolic Disease · 2026-01 · 49 (1)
DOI: 10.1002/jimd.70147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 22.01.2026. Verfasst von Paloma Martín-Jimenez und 16 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular Diseases Unit, Neurology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. Hauptthemen laut MEDLINE: Mitochondrial Myopathies, Thymidine Kinase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, European Union, European Commission.
Abstract (Originalsprache)
Thymidine kinase 2 deficiency (TK2d) is an ultra‐rare autosomal recessive mitochondrial myopathy with variable presentations, including late‐onset forms beginning after age 12. Unlike early‐onset disease, the natural history of late‐onset TK2d remains poorly defined. We conducted a prospective, single‐centre natural history study of 11 untreated patients with late‐onset TK2d over 24 months. The median age at symptom onset was 27.2 years. Clinical phenotypes included progressive myopathy ( n = 7), chronic progressive external ophthalmoplegia plus ( n = 2), and exercise intolerance ( n = 2). Most patients (72%) required non‐invasive ventilation, and 70% showed axonal polyneuropathy. All patients carried biallelic pathogenic TK2 variants, with p.Lys202del being the most common (13/22 alleles). Muscle biopsies demonstrated mitochondrial DNA depletion and multiple deletions, and muscle MRI consistently showed selective involvement of the sartorius , gracilis and gluteus maximus , whose fat fraction correlated with motor impairment. Functional assessments revealed a mean forced vital capacity of 70.4%, an NSAA score of 25.9, a six‐minute walk distance of 479.5 m, and a 100‐m run time of 60.5 s. Serum GDF15 levels were elevated (median 2747.5 pg/mL) and significantly correlated with motor and respiratory function. Over 2 years, patients showed measurable clinical deterioration, with declines in NSAA (−2.65 points), FVC (−9.11%), and worsening 100‐meter run times (+6 s). This study provides the first prospective longitudinal characterization of late‐onset TK2d and identifies clinically relevant, quantifiable outcomes that may inform future therapeutic trials targeting this underrepresented patient population. Moreover, these results are also relevant for the design of clinical trials in other mitochondrial myopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuromuscular Diseases Unit, Neurology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Medical-Surgical Sciences Research, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
- Mitochondrial and Neuromuscular Research Group '12 de Octubre', Hospital Research Institute (imas12), Madrid, Spain.
- Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
- Neuropathology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Pulmonology Department, Mechanical Ventilation and Neuromuscular Disorders Unit, Hospital 12 de Octubre, Madrid, Spain.
ORCID-Profile: Paloma Martín-Jimenez, Adrián González Quintana, Cristina Martín-Arriscado Arroba, Alberto Blázquez
Förderung
- Instituto de Salud Carlos III
- European Union
- European Commission
Zitieren
APA
Martín-Jimenez, P., Bermejo-Guerrero, L., Ochoa, L. E., Navarro-Riquelme, M., Garrido-Moraga, R., Hernández-Laín, A., Hernández-Voth, A., González Quintana, A., Bermejo-Moriñigo, A., González-Méndez, V., Martín-Arriscado Arroba, C., Smirnov, D., Konstantinovskiy, N., Arenas, J., Martin, M. Á., Blázquez, A., & Domínguez-González, C. (2026). Exploring Outcome Measures for Mitochondrial Myopathies; Insights From a Longitudinal Study on TK2 Deficiency. Journal of Inherited Metabolic Disease, 49(1). https://doi.org/10.1002/jimd.70147
Vancouver
Martín-Jimenez P, Bermejo-Guerrero L, Ochoa LE, Navarro-Riquelme M, Garrido-Moraga R, Hernández-Laín A, et al. Exploring Outcome Measures for Mitochondrial Myopathies; Insights From a Longitudinal Study on TK2 Deficiency. Journal of Inherited Metabolic Disease. 2026;49(1). doi:10.1002/jimd.70147
BibTeX
@article{MartnJimenez2026,
author = {Martín-Jimenez, Paloma and Bermejo-Guerrero, Laura and Ochoa, Luz Edith and Navarro-Riquelme, María and Garrido-Moraga, Rocío and Hernández-Laín, Aurelio and Hernández-Voth, Ana and González Quintana, Adrián and Bermejo-Moriñigo, Ana and González-Méndez, Violeta and Martín-Arriscado Arroba, Cristina and Smirnov, Dimitrii and Konstantinovskiy, Nikita and Arenas, Joaquín and Martin, Miguel Ángel and Blázquez, Alberto and Domínguez-González, Cristina},
title = {Exploring Outcome Measures for Mitochondrial Myopathies; Insights From a Longitudinal Study on TK2 Deficiency},
journal = {Journal of Inherited Metabolic Disease},
year = {2026},
volume = {49},
number = {1},
doi = {10.1002/jimd.70147}
}
EUVIMED